Inovio Pharmaceuticals Inc. (INO)

2.35
NASDAQ : Health Technology
Prev Close 2.20
Day Low/High 2.20 / 2.39
52 Wk Low/High 1.92 / 5.47
Avg Volume 624.40K
Exchange NASDAQ
Shares Outstanding 100.01M
Market Cap 220.02M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Inovio Pharmaceuticals To Present At Upcoming Investor Conferences

Inovio Pharmaceuticals To Present At Upcoming Investor Conferences

PLYMOUTH MEETING, Pa., Sept.

Inovio Completes Enrollment Of Its VGX-3100 Open-label Phase 2 Trial For Treatment Of HPV-Related High-Grade Anal Dysplasia

Inovio Completes Enrollment Of Its VGX-3100 Open-label Phase 2 Trial For Treatment Of HPV-Related High-Grade Anal Dysplasia

Company to report preliminary efficacy data later this year

Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results

Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results

PLYMOUTH MEETING, Pa., Aug.

Inovio Closes $15 Million Private Placement Of Convertible Bonds To Institutional Investors In Korea

Inovio Closes $15 Million Private Placement Of Convertible Bonds To Institutional Investors In Korea

Inovio Intends to Pursue Secondary Listing on Korea Exchange (KRX)

Inovio Pharmaceuticals To Report Second Quarter 2019 Financial Results On August 8, 2019

Inovio Pharmaceuticals To Report Second Quarter 2019 Financial Results On August 8, 2019

PLYMOUTH MEETING, Pa., July 30, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio's Positive First-in-Human MERS Vaccine Results Published In The Lancet Infectious Diseases

Inovio's Positive First-in-Human MERS Vaccine Results Published In The Lancet Infectious Diseases

PLYMOUTH MEETING, Pa., July 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Interesting INO Call Options For September 20th

Interesting INO Call Options For September 20th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the September 20th expiration.

Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates

Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates

Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, and Staff by 28%

Geneos Therapeutics Announces First Patient Dosed With Its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

Geneos Therapeutics Announces First Patient Dosed With Its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

This is the First-in-Human Implementation for Geneos Therapeutics' Exquisitely Personalized Immunotherapies for Cancer (GT-EPIC) Platform

Inovio Completes Enrollment Of VGX-3100 Phase 2 Trial For The Treatment Of HPV-Related Vulvar Dysplasia (VIN)

Inovio Completes Enrollment Of VGX-3100 Phase 2 Trial For The Treatment Of HPV-Related Vulvar Dysplasia (VIN)

Biotech company will report interim data later this year

Inovio Completes Enrollment Of VGX-3100 Phase 3 Trial (REVEAL 1) For The Treatment Of HPV-Related Cervical Pre-cancer

Inovio Completes Enrollment Of VGX-3100 Phase 3 Trial (REVEAL 1) For The Treatment Of HPV-Related Cervical Pre-cancer

PLYMOUTH MEETING, Pa., June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Receives $8.14 Million Award To Support Further Development Of Its Commercial Skin Delivery Device

Inovio Receives $8.14 Million Award To Support Further Development Of Its Commercial Skin Delivery Device

PLYMOUTH MEETING, Pa., June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio First To Advance Lassa Fever Candidate Vaccine Into A Clinical Trial

Inovio First To Advance Lassa Fever Candidate Vaccine Into A Clinical Trial

Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations

First Week Of June 21st Options Trading For Inovio Pharmaceuticals (INO)

First Week Of June 21st Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the June 21st expiration.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Risk and reward are the yin and yang of investing, and are closely related, especially in the pharmaceutical field.

First Week Of INO November 15th Options Trading

First Week Of INO November 15th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 15th expiration.

INO Crosses Below Key Moving Average Level

INO Crosses Below Key Moving Average Level

In trading on Tuesday, shares of Inovio Pharmaceuticals Inc. crossed below their 200 day moving average of $4.77, changing hands as low as $4.72 per share.

Inovio Pharmaceuticals (INO) Shares Cross Above 200 DMA

Inovio Pharmaceuticals (INO) Shares Cross Above 200 DMA

In trading on Monday, shares of Inovio Pharmaceuticals Inc. crossed above their 200 day moving average of $4.76, changing hands as high as $4.96 per share.

Interesting INO Put And Call Options For August 16th

Interesting INO Put And Call Options For August 16th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the August 16th expiration.

Interesting INO Put And Call Options For October 19th

Interesting INO Put And Call Options For October 19th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the October 19th expiration.

Bullish Two Hundred Day Moving Average Cross - INO

Bullish Two Hundred Day Moving Average Cross - INO

In trading on Tuesday, shares of Inovio Pharmaceuticals Inc. crossed above their 200 day moving average of $4.51, changing hands as high as $4.54 per share.

Interesting INO Put And Call Options For February 2019

Interesting INO Put And Call Options For February 2019

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the February 2019 expiration.

First Week Of July 20th Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the July 20th expiration.

Interesting INO Call Options For June 15th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the June 15th expiration.

Exiting Position With a Nice Profit

We are selling all of our shares of Marrone Bio Innovations, as news of common offering changes the game for us.

TheStreet Quant Rating: D- (Sell)